More reliable measurements for early diagnosis of Alzheimer’s disease

© Ocskay Bence -

JRC scientists contributed to the evaluation of the method performance related to the quantification of Alzheimer’s biomarkers. The study revealed the importance of developing a certified reference material, which is currently in progress at the JRC-Institute for Reference Materials and Measurements (IRMM).

The measurement of biomarkers, such as the peptide amyloid-β 1-42 can help in the early diagnosis of Alzheimer’s disease. However, this requires that measurements be standardised so that the results can be compared over time and between patients.A recent collaborative study has shown that different reference measurement methods for amyloid-β 1-42 can give comparable results, provided that a reference material is used for calibration. Consequently, the JRC-IRMM is currently developing certified reference materials for amyloid-β 1-42  measurements in close collaboration with international organisations, such as the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and the Alzheimer’s Association.
Read more in: J. Pannee et al.: “Round robin test on quantification of amyloid-β 1-42 in cerebrospinal fluid by mass spectrometry“,  Alzheimer’s and Dementia 12 (2016) 55-59, doi:10.1016/j.jalz.2015.06.1890